Lead Product(s): Hafnium dioxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Deal Size: $11.1 million Upfront Cash: Undisclosed
Deal Type: Financing June 08, 2020
The financing will help ensure the company have the necessary resources to continue achieving its goals to advance the development of NBTXR3.